

Invited Faculty / Speakers

Frantisek Antos
University of Prague

Hans Günter Becker
Westpfalz Klinikum
Kaiserslautern

Jan Braess
Hospital Barmherzige Brüder
Regensburg

Tom Cecil
Hampshire Hospitals NHS
Foundation Trust

László Damjanovich
Institute of Surgery
University of Debrecen

Marcello Deraco
Fondazione IRCCS Istituto
Nazionale dei Tumori, Milan

Stefan Eggeling
Vivantes Klinikum Neukölln, Berlin

Jesus Esquivel
Cancer Treatment Centers of
America (CTCA), Philadelphia

Matthias Evert
University Hospital Regensburg

Christoph-T. Germer
University Hospital of Würzburg

Gabriel Glockzin
Städtisches Klinikum München
Bogenhausen

Thomas Gruenberger
Rudolfstiftung Hospital, Wien

Hans-Stefan Hofmann
University Hospital Regensburg

Jörg Kalff
University Hospital Bonn

Monika Klinkhammer-Schalke
Cancer Center, University Hospital
Regensburg

Alfred Königsrainer
University Hospital Tübingen

Hauke Lang
University Medical Center Mainz

Sven A. Lang
University Hospital Regensburg

Dietmar Lorenz
Klinikum Offenbach

Aviram Nissan
The Chaim Sheba Medical Center
Tel Hashomer

Philip B. Paty
Memorial Sloan Kettering Cancer
Center, New York

Jörg Pelz
University Hospital Würzburg

Joachim Pfannschmidt
Helios Klinikum Emil v. Bering,
Berlin

Wojciech Polkowski
Medical University of Lublin

Johann Pratschke
Charité Berlin

Francois Quenet
Institut du Cancer de Montpellier

Beate Rau
Charité Berlin, Campus Mitte

Joachim Schirren
Horst Schmidt Kliniken Wiesbaden

Thomas Schneider
St. Vincentius-Kliniken, Karlsruhe

Viorel Scripcariu
University of Medicine and
Pharmacy "Gr.T.Popa" Iasi-Romania

Christian Stroszczyński
University Hospital Regensburg

Paul H. Sugarbaker
Washington Cancer Institute

Tamas Szöke
Hospital Barmherzige Brüder
Regensburg

Andreas Teufel
University Hospital Regensburg

Ali Ekrim Unal
University of Ankara

Victor J. Verwaal
University Medical Center Utrecht

Hideaki Yano
National Centre for Global Health
and Medicine, Tokyo

Nils Zorger
Hospital Barmherzige Brüder
Regensburg

Foto: UKR, Dieter Pirner, www.diegotal.de
Stand: März 2015

General Information

Scientific Leadership

Prof. Dr. Pompiliu Piso
Hospital Barmherzige Brüder Regensburg

Prof. Dr. Hans J. Schlitt
University Hospital Regensburg

Congress Secretary

PD Dr. Sven A. Lang (sven.lang@ukr.de)

Congress Venue

Hospital Barmherzige Brüder
Large Auditorium
House St. Vinzenz, 3rd Floor
Prüfeninger Str. 86
93049 Regensburg

Congress Management

Britta Haseneder
University Hospital Regensburg
93042 Regensburg, Germany
Phone: +49 941 944-4230 Fax: +49 941 944-4233
E-mail: kongresse@ukr.de

Information and registration

www.abdominal-metastatic-cancer2015.de

Congress Fee

| | |
|--------------------|-------|
| Both days | 175 € |
| Thursday, July 9th | 150 € |
| Friday, July 10th | 100 € |

Registration conditions

After your successful registration you will receive an invoice concerning your participation fee during the next days by email. Once registered your registration is binding. All payments must be made prior to the conference. Participation fees are due upon receipt of invoice without deduction. Please transfer the invoice amount before the event date. In case of a cancellation the cancellation statement must be in writing. The following processing fees apply: 8-3 working days before the event 50% of participation fee. In case of too late cancellation or absence without written cancellation the entire fee will be charged. A substitute participant may be submitted at any time.

Sponsors

| | |
|--------------------------------------|---------|
| Amgen | 1.000 € |
| Baxter | 1.000 € |
| Covidien Deutschland GmbH | 2.000 € |
| gd medical ag | 1.000 € |
| Kardialgut GmbH & Eight Medical | 5.000 € |
| KCI Medizinprodukte GmbH | 500 € |
| RanD S.r.l. | 1.000 € |
| Roche Pharma AG | 1.000 € |
| RTI Surgical - Tutogen Medical GmbH | 1.000 € |
| Sanofi-Aventis Deutschland GmbH | 500 € |
| Sirtex Medical Europe GmbH | 1.000 € |
| Synlab Services GmbH | 1.000 € |
| Takeda Pharma Vertrieb GmbH & Co. KG | 2.000 € |
| ThermaSolutions Inc. | 1.000 € |

We thank all sponsors of the conference for their kind support. Sponsoring performance for booth fee and advertising purposes.

7th International
Symposium
on

Abdominal
Metastatic Cancer



program

July 9th & 10th, 2015

Hospital Barmherzige Brüder Regensburg and
University Hospital Regensburg



www.abdominal-metastatic-cancer2015.de

Supported by

REGENSBURGER UNIVERSITÄTS
STIFTUNG
HELGA UND ERWIN HARTL

Dear colleagues,

treatment of metastatic disease is a major problem in patients with gastrointestinal or gynecological malignancies. For a long time, this condition was considered untreatable. However, due to multidisciplinary approaches, this has changed within the last decades. In colorectal cancer, resection has become the standard therapy and resectability of liver lesions has improved due to novel techniques (e.g. in-situ splitting) or strategies (e.g. neoadjuvant therapy). Furthermore, lung metastases from colorectal cancer can be successfully treated by surgical resection and even combined liver and lung resection provides cure in selected patients. For peritoneal metastases cytoreductive surgery (visceral resection and peritonectomy procedures) along with hyperthermic intraperitoneal chemotherapy (HIPEC) and systemic chemotherapy is recommended in the German guideline for the treatment of carcinomatosis originating from colorectal cancer. Following this, new programs for peritonectomy and HIPEC are now being established all over the world.

We would like to invite you to discuss all currently available treatment options and controversial issues in this important field of oncology. For the first time, we have also included the treatment of pulmonary metastases into the program to emphasize the curative opportunities offered for these patients.

Should you be interested in participating, please contact the Congress Management of the University Hospital Regensburg.

Regarding the current status of the program please access our website www.abdominal-metastatic-cancer2015.de.

The organizing team is looking forward to welcome you in Regensburg in July 2015!



Prof. Dr.
Pompiliu Piso



Prof. Dr.
Hans J. Schlitt



PD Dr.
Sven Lang

| | |
|--------------------|---|
| 08:45 - 09:00 | Opening Pise |
| Session I | Chairman Germer |
| 09:00 - 09:15 | Defining resectability for liver metastases <i>Schlitt</i> |
| 09:15 - 09:30 | Strategies to increase resectability: neoadjuvant downsizing <i>Gruenberger</i> |
| 09:30 - 09:45 | Defining response after neoadjuvant therapy for CRLM <i>Evert</i> |
| 09:45 - 10:00 | Role of adjuvant chemotherapy for liver metastases <i>Teufel</i> |
| 10:00 - 10:30 | Key note lecture: When and how to treat the colorectal primary in cases with liver metastases <i>Paty</i> |
| 10:30 - 11:00 | Discussion |
| 11:00 - 11:30 | Coffee break |
| Session II | Chairman Gruenberger |
| 11:30 - 11:45 | How to avoid postoperative liver failure? <i>Pratschke</i> |
| 11:45 - 12:00 | Surgical technique – how to dissect liver parenchyma best? <i>Piso</i> |
| 12:00 - 12:15 | Complication management and pitfalls in liver surgery <i>Lang H</i> |
| 12:15 - 12:30 | Technical approaches to increase resectability: 2-stage hepatectomy and PVE <i>Quenet</i> |
| 12:30 - 12:45 | Update on in-situ splitting / ALPPS <i>Lang S</i> |
| 12:45 - 13:00 | Interventional therapy of colorectal liver metastases <i>Stroszczyński</i> |
| 13:00 - 13:30 | Discussion |
| 13:30 - 14:30 | Lunch |
| Session III | Chairman Lang H |
| 14:30 - 15:00 | Key note lecture: Intraarterial chemotherapy for liver metastases <i>Paty</i> |
| 15:00 - 15:15 | Radiologic imaging for liver and peritoneal metastases <i>Zorger</i> |
| 15:15 - 15:30 | Nationwide analysis on detection and treatment of liver metastases in Germany <i>Klinkhammer-Schalke</i> |
| 15:30 - 15:45 | Surgery for peritoneal and liver metastases <i>Cecil</i> |
| 15:45 - 16:00 | Single centre experience of CRS and HIPEC in elderly - lessons learned <i>Königsrainer</i> |
| 16:00 - 16:30 | Coffee break |
| Session IV | Chairman Glockzin |
| 16:30 - 18:00 | Free papers liver and peritoneum à 10 min |
| | Paper 1 Difficulties in setting up, the first HIPEC Unit, in the North-Eastern Region of Romania <i>Scripcariu</i> |
| | Paper 2 Pelvic exenterations with Bricker type conduits in the cases of primary recto-sigmoid tumors - is it indicated in patients with isolated liver or peritoneal metastases? <i>Damjanovich</i> |
| | Paper 3 Combination of HIPEC with simultaneous bilateral HIThOC after cytoreductive surgery <i>Becker</i> |
| | Paper 4 Predictors of early recurrence after CRS+HIPEC for peritoneal metastasis of colorectal origin <i>Nissan</i> |
| 19:00 | Paper 5 - 8 Bavarian evening Restaurant „Haus Heuport“, Domplatz 7, 93047 Regensburg |

| | |
|--------------------|--|
| Session I | Chairman Lorenz |
| 09:00 - 09:30 | Key note lecture: My 10 golden rules for a successful cytoreduction <i>Sugarbaker</i> |
| 09:30 - 09:45 | Treatment of peritoneal surface malignancy from colorectal origin in Japan - current status and future perspectives <i>Yano</i> |
| 09:45 - 10:00 | Why is the US attitude towards CRS and HIPEC different? <i>Esquivel</i> |
| 10:00 - 10:15 | Starting a PSM programme – recommendations and “no go’s” <i>Deraco</i> |
| 10:15 - 10:30 | Present and future studies on HIPEC in France <i>Quenet</i> |
| 10:30 - 10:45 | What was new at the world congress on PSM in Amsterdam, future trends? <i>Verwaal</i> |
| 10:45 - 11:00 | Discussion |
| Session II | Chairman Antos |
| 11:00 - 11:30 | Surgical technique of CRS and HIPEC. My tips and tricks for - right upper quadrant <i>Sugarbaker</i> |
| 11:30 - 11:45 | left upper quadrant <i>Esquivel</i> |
| 11:45 - 12:00 | small pelvis <i>Paty</i> |
| 12:00 - 12:15 | lower abdomen <i>Piso</i> |
| 12:15 - 12:30 | HIPEC <i>Pelz</i> |
| 12:30 - 12:45 | perioperative management <i>Rau</i> |
| 12:45 - 13:00 | Discussion |
| 13:00 - 13:30 | Lunch |
| 13:30 - 14:30 | Chairman Kalff |
| Session III | Systemic chemotherapy for peritoneal metastasis <i>Braess</i> |
| 14:30 - 14:15 | Key Points and Overview of CRS and HIPEC for Colorectal Peritoneal Metastases <i>Cecil</i> |
| 15:00 - 15:15 | Patient outcome and quality of life after CRS and HIPEC <i>Polkowski</i> |
| 15:15 - 15:30 | Pitfalls during the learning curve <i>Unal</i> |
| 15:30 - 15:45 | Discussion |
| 15:45 - 16:00 | Coffee break |
| 16:00 - 16:30 | Chairman Hofmann |
| Session IV | Lung metastases of colorectal cancer |
| 16:30 - 16:45 | Surgical intervention for pulmonary metastases from colorectal carcinoma <i>Pfannschmidt</i> |
| 16:45 - 17:00 | Thoracoscopic or Open Surgery for Pulmonary Metastasectomy? <i>Eggeling</i> |
| 17:00 - 17:15 | Lung- und Livermetastases of Colorectal Cancer: A contraindication for pulmonary metastasectomy? <i>Schirren</i> |
| 17:15 - 17:30 | Is mediastinal lymphadenectomy during pulmonary metastasectomy of colorectal cancer necessary? <i>Szöke</i> |
| 17:30 - 17:45 | Alternative for metastasectomy: Radiofrequency ablation and Stereotactic Body Radiation Therapy (SBRT)? <i>Schneider</i> |
| 17:45 - 18:00 | Discussion |
| 18:00 | Closing remarks and End of meeting |